AbbVie (AbbVie (ABBV)) shares ticked up slightly on Friday after the company dropped some impressive long-term data at the European Hematology Association (EHA) 2026 Congress. The news centers on its venetoclax-based therapy for chronic lymphocytic leukemia (CLL), and the numbers are the kind that make oncologists sit up and take notice.

The data comes from the Phase 3 CLL14 trial, which compared a fixed-duration combo of venetoclax plus obinutuzumab against chlorambucil plus obinutuzumab in previously untreated CLL patients who also had other medical conditions. That's a tough patient population, but the results suggest the venetoclax combo keeps the disease at bay for a very long time.

After a median follow-up of 9.2 years, patients on venetoclax plus obinutuzumab had a median progression-free survival (PFS) of 6.4 years, compared to just 3.2 years for the control group. That's more than double. And the median time to next treatment (TTNT) was 7.6 years, meaning most patients didn't need another therapy for over seven and a half years. That's a big deal for a fixed-duration regimen—patients get a finite course of treatment and then stay in remission for years.

The nine-year analysis also reinforced the safety profile of the combo, with no new red flags. AbbVie is clearly betting that this kind of long-term data will solidify venetoclax's position in the CLL treatment landscape.

What AbbVie's Edge Scorecard Says

MarketDash's Edge scorecard gives AbbVie a mixed picture. The quality score is stellar at 99.2, reflecting a healthy balance sheet. But the value score is a low 12.85, meaning the stock trades at a steep premium compared to peers. Growth comes in at 41.88, indicating moderate potential, and momentum is 43.66—again moderate. The verdict: AbbVie is a solid company with strong fundamentals, but the premium valuation and moderate momentum suggest it may need fresh catalysts to keep climbing.

ETF Exposure: Why ABBV Moves With These Funds

AbbVie is a heavyweight in several healthcare ETFs, which means fund flows can directly impact the stock. Here are the funds with the biggest ABBV weightings:

• VanEck Healthcare TruSector ETF (TRUH): 6.94% weight
• The Health Care Select Sector SPDR Fund (XLV): 8.28% weight
• State Street Health Care Select Sector SPDR ETF (XLV): 7.24% weight

Because ABBV carries such heavy weight in these funds, any significant inflows or outflows for these ETFs will likely force automatic buying or selling of the stock. It's a reminder that sometimes a stock's moves are less about its own news and more about what's happening in the broader ETF ecosystem.

ABBV Price Action: AbbVie shares were up 0.41% at $225.70 at the time of publication on Friday.